CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail| Bid procedure, 2025-09-05 | |
| Bonds | SWEDISH GOVERNMENT: 1060. SE0009496367. 2028-05-12 SWEDISH GOVERNMENT: 1056, SE0004517290, 2032-06-01 |
| Bid date | 2025-09-05 |
| Bid times | 09.00-10.00 (CET/CEST) on the Bid date |
| Offered volume (corresponding nominal amount) | 1060: 1500 million SEK +/-1500 million SEK 1056: 1500 million SEK +/-1500 million SEK |
| Highest permitted bid volume (corresponding nominal amount) | 1060: 1500 million SEK per bid 1056: 1500 million SEK per bid |
| Lowest permitted bid volume (corresponding nominal amount) | SEK 10 million per bid |
| Expected allocation time | Not later than 10.15 (CET/CEST) on the Bid date |
| Delivery and payment date | 2025-09-09 |
| Settlement amount | To be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK |
Stockholm, 2025-08-29
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
- Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction
- Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Pati
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
